Travere Therapeutics (TVTX) CMO logs Rule 10b5-1 and tax-cover share sales

Rhea-AI Filing Summary

Travere Therapeutics’ Chief Medical Officer sells shares tied to equity awards and a trading plan. Reporting person Jula Inrig, Chief Medical Officer of Travere Therapeutics, Inc., reported two sales of common stock. On January 5, 2026, 2,031 shares were sold at $40.18 per share, and on January 6, 2026, 445 shares were sold at $37.75 per share. After these transactions, the reporting person held 86,311 shares of common stock directly.

According to the footnotes, the January 5 sale reflects shares sold to cover tax withholding owed when restricted stock units vested, under the company’s equity incentive plan and a mandated “sell to cover” arrangement, and is described as not a discretionary trade. The January 6 sale was made under a written plan adopted on May 28, 2025 that is intended to comply with Rule 10b5-1(c), and it also includes shares sold to cover tax obligations from vesting restricted stock units.

Insider Trade Summary

Net Seller: 2,476 shares ($98,404)

Net Sell 2 txns

Insider Inrig Jula

Role CHIEF MEDICAL OFFICER

Sold 2,476 shs ($98K)

Type	Security	Shares	Price	Value
Sale	Common Stock	445	$37.75	$17K
Sale	Common Stock	2,031	$40.18	$82K

Holdings After Transaction: Common Stock — 86,311 shares (Direct)

Footnotes (1)

1. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Inrig Jula

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S(1)		2,031	D	$40.18	86,756	D
Common Stock	01/06/2026		S(2)		445	D	$37.75	86,311	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

2. This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Travere Therapeutics (TVTX) disclose for its Chief Medical Officer?

The Chief Medical Officer, Jula Inrig, reported two sales of Travere Therapeutics, Inc. common stock. On January 5, 2026, 2,031 shares were sold at $40.18 per share, and on January 6, 2026, 445 shares were sold at $37.75 per share, leaving 86,311 shares held directly after the reported transactions.

Why were some Travere Therapeutics (TVTX) shares sold by the Chief Medical Officer on January 5, 2026?

The filing explains that the 2,031 shares sold on January 5, 2026 represent the number of shares required to be sold to cover tax withholding obligations arising from the settlement of vested restricted stock units. The sale was mandated by the issuer’s equity incentive plans through a “sell to cover” transaction with a designated brokerage firm and is described as not a discretionary trade by the reporting person.

What is the significance of the Rule 10b5-1 trading plan mentioned for Travere Therapeutics (TVTX)?

The filing states that the January 6, 2026 sale of 445 shares was made under a written plan adopted on May 28, 2025 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934. Such a plan allows pre-arranged trades when certain conditions are met, and in this case also includes sales of shares to cover tax obligations triggered by the vesting of restricted stock units.

How many Travere Therapeutics (TVTX) shares does the Chief Medical Officer hold after these transactions?

After the reported transactions on January 5 and 6, 2026, the Chief Medical Officer is shown as directly owning 86,311 shares of Travere Therapeutics, Inc. common stock.

Were the Travere Therapeutics (TVTX) insider sales discretionary trades by the Chief Medical Officer?

The filing notes that the January 5, 2026 sale was mandated under the issuer’s equity incentive plans as a “sell to cover” to satisfy tax withholding on vested restricted stock units and is described as not a discretionary trade. The January 6, 2026 sale was executed under a pre-established Rule 10b5-1(c) trading plan and includes sales to cover tax obligations upon vesting of restricted stock units.